Tanfac Industries Ltd
Incorporated in 1972, Tanfac Industries Ltd is amongst the leading producers of Hydrofluoric Acid and its derivatives.
- Market Cap ₹ 4,151 Cr.
- Current Price ₹ 4,161
- High / Low ₹ 5,064 / 2,510
- Stock P/E 55.5
- Book Value ₹ 340
- Dividend Yield 0.22 %
- ROCE 41.8 %
- ROE 32.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 38.6% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.1%
Cons
- Stock is trading at 12.2 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Part of BSE Allcap BSE Commodities
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117 | 120 | 133 | 126 | 162 | 222 | 165 | 148 | 320 | 375 | 378 | 557 | 690 | |
| 106 | 112 | 125 | 112 | 141 | 169 | 138 | 115 | 244 | 299 | 306 | 426 | 572 | |
| Operating Profit | 11 | 8 | 9 | 14 | 21 | 53 | 27 | 33 | 76 | 76 | 72 | 131 | 117 |
| OPM % | 10% | 7% | 7% | 11% | 13% | 24% | 16% | 22% | 24% | 20% | 19% | 24% | 17% |
| 0 | 1 | 4 | 1 | 0 | 1 | 1 | 1 | 3 | 8 | 7 | 3 | 3 | |
| Interest | 10 | 10 | 8 | 7 | 7 | 4 | 2 | 1 | 2 | 2 | 2 | 5 | 5 |
| Depreciation | 7 | 6 | 5 | 5 | 5 | 8 | 5 | 8 | 6 | 6 | 7 | 10 | 17 |
| Profit before tax | -6 | -7 | 0 | 3 | 10 | 42 | 22 | 25 | 72 | 75 | 70 | 119 | 99 |
| Tax % | -45% | -20% | -8% | 0% | 1% | 14% | 22% | 30% | 26% | 26% | 25% | 26% | |
| -3 | -5 | 0 | 3 | 10 | 36 | 17 | 17 | 53 | 56 | 52 | 88 | 75 | |
| EPS in Rs | -3.04 | -5.30 | 0.40 | 3.30 | 9.70 | 36.06 | 17.01 | 17.51 | 53.41 | 56.27 | 52.61 | 88.37 | 75.03 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 17% | 12% | 13% | 10% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 28% |
| 3 Years: | 20% |
| TTM: | 41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 39% |
| 3 Years: | 18% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 66% |
| 5 Years: | 74% |
| 3 Years: | 65% |
| 1 Year: | 34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 30% |
| Last Year: | 32% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | -5 | -10 | -10 | -7 | 3 | 38 | 55 | 73 | 124 | 174 | 220 | 302 | 330 |
| 70 | 69 | 61 | 54 | 43 | 12 | 0 | 0 | 0 | 0 | 0 | 41 | 31 | |
| 31 | 26 | 30 | 20 | 29 | 48 | 24 | 37 | 49 | 68 | 71 | 73 | 91 | |
| Total Liabilities | 106 | 95 | 91 | 77 | 86 | 107 | 89 | 120 | 182 | 252 | 301 | 426 | 462 |
| 59 | 53 | 49 | 45 | 41 | 34 | 33 | 40 | 40 | 55 | 61 | 168 | 197 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 3 | 12 | 6 | 29 | 8 | 22 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 23 | 42 | 67 | 67 | 9 | 9 |
| 46 | 42 | 42 | 31 | 44 | 71 | 49 | 55 | 88 | 124 | 145 | 242 | 234 | |
| Total Assets | 106 | 95 | 91 | 77 | 86 | 107 | 89 | 120 | 182 | 252 | 301 | 426 | 462 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 9 | 16 | 16 | 17 | 37 | 22 | 37 | 44 | 43 | 34 | 33 | |
| -0 | 0 | -1 | -1 | -1 | -3 | -9 | -34 | -35 | -40 | -30 | -42 | |
| -19 | -10 | -15 | -15 | -17 | -34 | -12 | -1 | -5 | -6 | -7 | 32 | |
| Net Cash Flow | -0 | -0 | -0 | 0 | -0 | 0 | -0 | 2 | 5 | -3 | -3 | 23 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 52 | 54 | 46 | 44 | 38 | 40 | 40 | 28 | 49 | 59 | 65 |
| Inventory Days | 136 | 106 | 82 | 66 | 75 | 107 | 75 | 134 | 91 | 89 | 100 | 112 |
| Days Payable | 113 | 89 | 97 | 69 | 74 | 90 | 47 | 142 | 76 | 78 | 77 | 48 |
| Cash Conversion Cycle | 80 | 68 | 39 | 42 | 45 | 54 | 67 | 31 | 43 | 60 | 82 | 129 |
| Working Capital Days | -162 | -150 | -124 | -109 | -53 | 35 | 65 | 36 | 33 | 46 | 59 | 62 |
| ROCE % | 6% | 4% | 7% | 18% | 29% | 78% | 37% | 35% | 67% | 48% | 33% | 42% |
Documents
Announcements
-
Intimation Of Fixation Of Record Date For Sub-Division Of The Equity Shares Of The Company
13h - Record date March 5, 2026 for 1:2 share sub-division; face value ₹10 to ₹5.
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
25 Feb - EGM Feb 23, 2026: approved share split, up to ₹500 crore equity raise (10,00,000 shares pre-split), Mr. Afzal appointed MD.
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
25 Feb - EGM (23 Feb 2026) approved share sub-division, up to ₹500 crore fundraise via QIP, and MD appointment.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
24 Feb - EGM Feb 23: five resolutions passed including share sub-division, Rs.500 crore fundraising, MD appointment, nominee director.
-
Summary Of Proceedings Of The Extra-Ordinary General Meeting (EGM) Of The Company
23 Feb - 23 Feb 2026 EGM: approved share split, capital alteration, ₹500 crore fundraising, Afzal Malkani designated MD, Sandhya Sharma appointed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
Product Portfolio
The company manufactures inorganic fluorine-based chemicals like Anhydrous Hydrofluoric acid, Sulphuric Acid, Oleum, Aluminum Fluoride, Potassium Fluoride, Potassium Bifluoride, Boron Trifluoride Complexes, Calcium Sulphate (Gypsum), IsoButyl Acetophenone, Acetic Acid, Peracetic Acid and Poly Aluminum Chloride, etc. [1]